GW’s Epidiolex results are worth mentioning

Whenever one of my biotech companies have good news. It almost always makes me smile. Yesterday it was GW. The shares of GW Pharmaceuticals (GWPH) are soaring on news that its cannabis-derived drug significantly diminished the seizure amount in children with a rare form of epilepsy in a phase-three trial. Epidiolex…

Continue reading